Archrock Inc. AROC 深 滬
已收盤 02-06 16:00:00 美东时间
32.05
+1.310
+4.26%
華盛通- 最 高32.42
- 今 開31.05
- 成交量 281.67万股
- 最 低 31.00
- 昨 收 30.74
- 總市值 56.21亿
- 52周最高 32.42
- 市盈率 靜 30.56
- 換手率 1.61%
- 52周最低 19.51
- 委 比 29.45%
- 總股本 1.75亿
- 歷史最高 32.42
- 量 比 1.39
- 振 幅 4.62%
- 歷史最低 -7.4855
- 每 手 1
- 風險率 1.62%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Archrock Inc. hat eine Aktualisierung ihres Finanzkalenders veröffentlicht
Archrock Inc. hat eine Aktualisierung ihres Finanzkalenders veröffentlicht Archrock Inc. wird am 25. Februar 2026 eine Telefonkonferenz abhalten, um die Finanz- und Betriebsergebnisse für das vierte Quartal und das Gesamtjahr 2025 sowie die Jahresprognose für 2026 zu präsentieren. Die Ergebnisse wer
02-04 05:15
Archrock Inc. to Announce Fourth Quarter and Full-Year Results with 2026 Guidance
Archrock Inc. to Announce Fourth Quarter and Full-Year Results with 2026 Guidance Archrock Inc. will release its fourth quarter and full-year 2025 financial and operating results prior to a conference call scheduled for Wednesday, February 25, 2026, at 8:30 a.m. Eastern Time. The results will be ava
02-04 05:15
Archrock Increases Quarterly Cash Dividend
Archrock, Inc. announced a 5% increase in its quarterly dividend to $0.22 per share, with the fourth quarter 2025 dividend of $0.88 annualized. The dividend will be paid on February 18, 2026, to stockholders of record on February 10, 2026. This represents a 16% increase from the fourth quarter 2024 dividend. Archrock, an energy infrastructure company, highlighted its focus on natural gas compression and growth potential in a constructive demand o...
01-29 21:15
Archrock Announces Closing of $800 Million of Senior Notes Offering
<p>Archrock Services, a wholly-owned subsidiary of Archrock, Inc., has completed a private offering of $800 million in 6.000% senior notes due 2034. Archrock Partners Finance Corp., a subsidiary of Archrock Services, is the co-issuer. Proceeds will be used to repay a portion of borrowings under Archrock’s revolving credit facility. The notes were sold to qualified institutional buyers under Rule 144A and to non-U.S. persons under Regulation S. Ar...
01-21 21:15
5 Strong-Buy Stocks Analysts Love in 2026
Holiday season is ideal for investors to recharge and reassess finances. Low market volume, light news cycle, and analyst ratings draw attention.
01-14 05:23
Archrock subsidiary launches $500M notes offering
Archrock (AROC) subsidiary Archrock Services plans to offer $500 million aggregate principal amount of senior notes due 2034. Archrock Partners Finance, a wholly-owned subsidiary of Archrock Partners,...
01-06 20:50
Archrock Plans To Launch $500M Senior Notes Offering Due 2034
Archrock, Inc. (NYSE: AROC) ("Archrock") today announced that Archrock Services, L.P. ("Archrock Services"), a wholly-owned subsidiary of Archrock, intends, subject to market and other conditions, to offer and sell to
01-06 20:46
Archrock Announces Private Offering of $500 Million of Senior Notes
Archrock Services, a subsidiary of Archrock, Inc., plans to offer and sell $500 million in senior notes due 2034. Archrock intends to use the net proceeds to repay part of its revolving credit facility. The notes will be offered to qualified institutional buyers under Rule 144A and non-U.S. persons under Regulation S. This press release does not constitute an offer or solicitation to buy or sell the securities. Archrock is an energy infrastructur...
01-06 12:41
Archrock Publishes its 2024 Annual Sustainability Report
Archrock, Inc. has released its 2024 Sustainability Report, highlighting achievements such as exceeding safety goals, reducing CO2 emissions, and advancing methane management. The report also details operational growth and strategic initiatives, aligning with sustainability frameworks like SASB and TCFD. Archrock emphasizes its commitment to cleaner energy solutions and sustainable business practices.
2025-11-20 21:18
美股大行评级 | 最高350美元！16家大行上调谷歌目标价！Meta遭12家大行下调目标价；潜在涨幅1456.29%！NRX Pharmaceuticals获Ascendiant Capital升目标价至47美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从46美元升至47美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从27美元升至31美元
2025-10-31 10:25
